Search Results - "TOPP, Max S"

Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma by Topp, Max S, Duell, Johannes, Zugmaier, Gerhard, Attal, Michel, Moreau, Philippe, Langer, Christian, Krönke, Jan, Facon, Thierry, Salnikov, Alexey V, Lesley, Robin, Beutner, Karl, Kalabus, James, Rasmussen, Erik, Riemann, Kathrin, Minella, Alex C, Munzert, Gerd, Einsele, Hermann

“…The anti-B-cell maturation antigen BiTE molecule AMG 420 was assessed in patients with relapsed/refractory multiple myeloma. In this first-in-human study, up…”
Get full text

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia by Kantarjian, Hagop, Stein, Anthony, Gökbuget, Nicola, Fielding, Adele K, Schuh, Andre C, Ribera, Josep-Maria, Wei, Andrew, Dombret, Hervé, Foà, Robin, Bassan, Renato, Arslan, Önder, Sanz, Miguel A, Bergeron, Julie, Demirkan, Fatih, Lech-Maranda, Ewa, Rambaldi, Alessandro, Thomas, Xavier, Horst, Heinz-August, Brüggemann, Monika, Klapper, Wolfram, Wood, Brent L, Fleishman, Alex, Nagorsen, Dirk, Holland, Christopher, Zimmerman, Zachary, Topp, Max S

“…Among adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia, treatment with the bispecific anti-CD19 and anti-CD3 monoclonal…”
Get full text

Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group by Fuchs, Michael, Goergen, Helen, Kobe, Carsten, Kuhnert, Georg, Lohri, Andreas, Greil, Richard, Sasse, Stephanie, Topp, Max S, Schäfer, Erhardt, Hertenstein, Bernd, Soekler, Martin, Vogelhuber, Martin, Zijlstra, Josée M, Keller, Ulrich Bernd, Krause, Stefan W, Wilhelm, Martin, Maschmeyer, Georg, Thiemer, Julia, Dührsen, Ulrich, Meissner, Julia, Viardot, Andreas, Eich, Hans, Baues, Christian, Diehl, Volker, Rosenwald, Andreas, von Tresckow, Bastian, Dietlein, Markus, Borchmann, Peter, Engert, Andreas

“…Combined-modality treatment (CMT) with 2× ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) and small-field radiotherapy is standard of care for…”
Get full text

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study by Topp, Max S, Dr, Gökbuget, Nicola, MD, Stein, Anthony S, MD, Zugmaier, Gerhard, MD, O'Brien, Susan, MD, Bargou, Ralf C, Prof, Dombret, Hervé, MD, Fielding, Adele K, PhD, Heffner, Leonard, MD, Larson, Richard A, Prof, Neumann, Svenja, MD, Foà, Robin, MD, Litzow, Mark, Prof, Ribera, Josep-Maria, Prof, Rambaldi, Alessandro, MD, Schiller, Gary, MD, Brüggemann, Monika, MD, Horst, Heinz A, MD, Holland, Chris, MS, Jia, Catherine, PhD, Maniar, Tapan, MD, Huber, Birgit, PhD, Nagorsen, Dirk, MD, Forman, Stephen J, MD, Kantarjian, Hagop M, Prof

“…Summary Background Adults with relapsed or refractory B-precursor acute lymphoblastic leukaemia have an unfavourable prognosis. Blinatumomab is a bispecific…”
Get full text

Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CT by Duell, Johannes, Krummenast, Franziska, Schirbel, Andreas, Klassen, Philipp, Samnick, Samuel, Rauert-Wunderlich, Hilka, Rasche, Leo, Buck, Andreas K, Wester, Hans-Jürgen, Rosenwald, Andreas, Einsele, Herrmann, Topp, Max S, Lapa, Constantin, Kircher, Malte

“…PET/CT with F-FDG is an integral component in the primary staging of most lymphomas. However, its utility is limited in marginal-zone lymphoma (MZL) because of…”
Get full text

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival by TOPP, Max S, KUFER, Peter, STELLJES, Matthias, SCHAICH, Markus, DEGENHARD, Evelyn, KÖHNE-VOLLAND, Rudolf, BRÜGGEMANN, Monika, OTTMANN, Oliver, PFEIFER, Heike, BURMEISTER, Thomas, NAGORSEN, Dirk, SCHMIDT, Margit, GÖKBUGET, Nicola, LUTTERBUESE, Ralf, REINHARDT, Carsten, BAEUERLE, Patrick A, KNEBA, Michael, EINSELE, Hermann, RIETHMÜLLER, Gert, HOELZER, Dieter, ZUGMAIER, Gerhard, BARGOU, Ralf C, GOEBELER, Mariele, KLINGER, Matthias, NEUMANN, Svenja, HORST, Heinz-A, RAFF, Thorsten, VIARDOT, Andreas, SCHMID, Mathias

“…Blinatumomab, a bispecific single-chain antibody targeting the CD19 antigen, is a member of a novel class of antibodies that redirect T cells for selective…”
Get full text

Hematopoietic stem cell involvement in BCR-ABL1–positive ALL as a potential mechanism of resistance to blinatumomab therapy by Nagel, Inga, Bartels, Marius, Duell, Johannes, Oberg, Hans-Heinrich, Ussat, Sandra, Bruckmueller, Henrike, Ottmann, Oliver, Pfeifer, Heike, Trautmann, Heiko, Gökbuget, Nicola, Caliebe, Almuth, Kabelitz, Dieter, Kneba, Michael, Horst, Heinz-August, Hoelzer, Dieter, Topp, Max S., Cascorbi, Ingolf, Siebert, Reiner, Brüggemann, Monika

“…The bispecific T-cell engager blinatumomab targeting CD19 can induce complete remission in relapsed or refractory B-cell precursor acute lymphoblastic leukemia…”
Get full text

Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial by VON TRESCKOW, Bastian, PLÜTSCHOW, Annette, ZIJLSTRA, Josée M, SOEKLER, Martin, STEIN, Harald, EICH, Hans T, MUELLER, Rolf P, DIEHL, Volker, BORCHMANN, Peter, ENGERT, Andreas, FUCHS, Michael, KLIMM, Beate, MARKOVA, Jana, LOHRI, Andreas, KRAL, Zdenek, GREIL, Richard, TOPP, Max S, MEISSNER, Julia

“…In patients with early unfavorable Hodgkin's lymphoma (HL), combined modality treatment with four cycles of ABVD (adriamycin, bleomycin, vinblastine, and…”
Get full text

Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia by Gökbuget, Nicola, Zugmaier, Gerhard, Klinger, Matthias, Kufer, Peter, Stelljes, Matthias, Viardot, Andreas, Horst, Heinz A, Neumann, Svenja, Brüggemann, Monika, Ottmann, Oliver G, Burmeister, Thomas, Wessiepe, Dorothea, Topp, Max S, Bargou, Ralf

Get full text

Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial by Behringer, Karolin, MD, Goergen, Helen, Dipl Math, Hitz, Felicitas, MD, Zijlstra, Josée M, MD, Greil, Richard, MD, Markova, Jana, MD, Sasse, Stephanie, MD, Fuchs, Michael, MD, Topp, Max S, MD, Soekler, Martin, MD, Mathas, Stephan, MD, Meissner, Julia, MD, Wilhelm, Martin, MD, Koch, Peter, MD, Lindemann, Hans-Walter, MD, Schalk, Enrico, MD, Semrau, Robert, MD, Kriz, Jan, MD, Vieler, Tom, MD, Bentz, Martin, MD, Lange, Elisabeth, MD, Mahlberg, Rolf, MD, Hassler, Andre, MD, Vogelhuber, Martin, MD, Hahn, Dennis, MD, Mezger, Jörg, MD, Krause, Stefan W, MD, Skoetz, Nicole, MD, Böll, Boris, MD, von Tresckow, Bastian, MD, Diehl, Volker, MD, Hallek, Michael, MD, Borchmann, Peter, MD, Stein, Harald, MD, Eich, Hans, MD, Engert, Andreas, Dr

“…Summary Background The role of bleomycin and dacarbazine in the ABVD regimen (ie, doxorubicin, bleomycin, vinblastine, and dacarbazine) has been questioned,…”
Get full text

The natural human IgM antibody PAT-SM6 induces apoptosis in primary human multiple myeloma cells by targeting heat shock protein GRP78 by Rasche, Leo, Duell, Johannes, Morgner, Charlotte, Chatterjee, Manik, Hensel, Frank, Rosenwald, Andreas, Einsele, Hermann, Topp, Max S, Brändlein, Stephanie

“…In contrast to other haematological malignancies, targeted immunotherapy has not entered standard treatment regimens for de novo or relapsed multiple myeloma…”
Get full text

GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6 by Rasche, Leo, Duell, Johannes, Castro, Inês C, Dubljevic, Valentina, Chatterjee, Manik, Knop, Stefan, Hensel, Frank, Rosenwald, Andreas, Einsele, Hermann, Topp, Max S, Brändlein, Stephanie

“…The primary objective of this phase 1 study was to evaluate the safety and tolerability of the anti-glucose regulated protein 78 monoclonal immunoglobulin M…”
Get full text

Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study by Shah, Bijal D, Ghobadi, Armin, Oluwole, Olalekan O, Logan, Aaron C, Boissel, Nicolas, Cassaday, Ryan D, Leguay, Thibaut, Bishop, Michael R, Topp, Max S, Tzachanis, Dimitrios, O'Dwyer, Kristen M, Arellano, Martha L, Lin, Yi, Baer, Maria R, Schiller, Gary J, Park, Jae H, Subklewe, Marion, Abedi, Mehrdad, Minnema, Monique C, Wierda, William G, DeAngelo, Daniel J, Stiff, Patrick, Jeyakumar, Deepa, Dong, Jinghui, Adhikary, Sabina, Zhou, Lang, Schuberth, Petra C, Faghmous, Imi, Masouleh, Behzad Kharabi, Houot, Roch

“…Brexucabtagene autoleucel (KTE-X19) is an autologous anti-CD19 CAR T-cell therapy approved in the USA to treat adult patients with relapsed or refractory…”
Get full text

General condition and comorbidity of long-term survivors of adult acute lymphoblastic leukemia by Gökbuget, Nicola, Ihrig, Kristina, Stadler, Michael, Stelljes, Matthias, Elmaagacli, Ahmet, Starck, Michael, Raffel, Simon, Stoltefuss, Andrea, Viardot, Andreas, Kreuzer, Karl-Anton, Heidenreich, Daniela, Renzelmann, Andrea, Wäsch, Ralph, Topp, Max S, Ritter, Barbara, Reimer, Peter, Beck, Joachim, Westermann, Jörg, Wendelin, Knut, Alakel, Nael, Hanoun, Maher, Serve, Hubert, Hoelzer, Dieter

“…Cure rates in adult acute lymphoblastic leukemia (ALL) improved using pediatric-based chemotherapy and stem cell transplantation (SCT). However, limited data…”
Get full text

Lymphoma-Sink Effect in Marginal Zone Lymphoma Based on CXCR4-Targeted Molecular Imaging by Kosmala, Aleksander, Seifert, Simone, Schneid, Simone, Dreher, Niklas, Higuchi, Takahiro, Weich, Alexander, Serfling, Sebastian E., Hartrampf, Philipp E., Einsele, Hermann, Buck, Andreas K., Topp, Max S., Duell, Johannes, Werner, Rudolf A.

“…Purpose Recent studies investigating a tumor-sink effect in solid tumors reported on decreasing uptake in normal organs in patients with higher tumor burden…”
Get full text

Severe treatment-refractory T-cell-mediated immune skin toxicities observed with obinutuzumab/rituximab-atezo-pola in two patients with follicular lymphoma by Topp, Max S, Duell, Johannes, Guijarro, Ana Maria Abajo, Odin, Marielle, Nielsen, Tina, Rajeswaran, Anand, Wenger, Michael, Zundel, Christelle, Bogucka-Fedorczuk, Aleksandra, Wrobel, Tomasz

Get full text

Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL by Nägele, Virginie, Kratzer, Andrea, Zugmaier, Gerhard, Holland, Chris, Hijazi, Youssef, Topp, Max S, Gökbuget, Nicola, Baeuerle, Patrick A, Kufer, Peter, Wolf, Andreas, Klinger, Matthias

“…Blinatumomab has shown a remission rate of 69% in an exploratory single-arm, phase II dose-escalation study in adult patients with relapsed/refractory…”
Get full text

Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia: Results of a pooled analysis by Topp, Max S., Stein, Anthony S., Gökbuget, Nicola, Horst, Heinz‐August, Boissel, Nicolas, Martinelli, Giovanni, Kantarjian, Hagop, Brüggemann, Monika, Chen, Yuqi, Zugmaier, Gerhard

“…Background Blinatumomab is a BiTE® immuno‐oncology therapy indicated for the treatment of patients with relapsed or refractory (r/r) B‐cell precursor (BCP)…”
Get full text

Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases by Rasche, Leo, Bernard, Corinna, Topp, Max S., Kapp, Markus, Duell, Johannes, Wesemeier, Carmen, Haralambieva, Eugenia, Maeder, Uwe, Einsele, Hermann, Knop, Stefan

“…Extramedullary (e) relapse in multiple myeloma (MM) has an adverse prognosis, but knowledge concerning biological features and preferred treatment is scarce…”
Get full text

Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma by Brouwer-Visser, Jurriaan, Fiaschi, Nathalie, Deering, Raquel P, Cygan, Kamil J, Scott, Darius, Jeong, Se, Boucher, Lauren, Gupta, Namita T, Gupta, Suraj, Adler, Christina, Topp, Max S, Bannerji, Rajat, Duell, Johannes, Advani, Ranjana H, Flink, Dina M, Chaudhry, Aafia, Thurston, Gavin, Ambati, Srikanth R, Jankovic, Vladimir

“…BackgroundPatients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL) have a significant need for effective treatment options. Odronextamab is an…”
Get full text